Selected research
Industry Research
Medical Radioisotopes Industry Research Report 2026
Market perspective
The global Medical Radioisotopes market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Medical Radioisotopes market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Medical Radioisotopes market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Medical Radioisotopes market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Medical Radioisotopes include NRG, IRE, ANSTO, NTP Radioisotopes, China National Nuclear Corporation, Rosatom, Nordion, Eckert & Ziegler Strahlen and Polatom. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Medical Radioisotopes market in terms of revenue (US$ million) and, where applicable, service volume (Tons), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Medical Radioisotopes.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Medical Radioisotopes Market by Company
NRG
IRE
ANSTO
NTP Radioisotopes
China National Nuclear Corporation
Rosatom
Nordion
Eckert & Ziegler Strahlen
Polatom
Medical Radioisotopes Segment by Type
Tc-99m
Cobalt-60
Iodine Radioisotopes
Medical Radioisotopes Segment by Application
Nuclear Therapy
Equipment Radioactive Source
Diagnosis
Others
Medical Radioisotopes Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medical Radioisotopes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medical Radioisotopes and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medical Radioisotopes.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Medical Radioisotopes companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tc-99m
- Cobalt-60
- Iodine Radioisotopes
Applications
- Nuclear Therapy
- Equipment Radioactive Source
- Diagnosis
- Others
Companies covered
- NRG
- IRE
- ANSTO
- NTP Radioisotopes
- China National Nuclear Corporation
- Rosatom
- Nordion
- Eckert & Ziegler Strahlen
- Polatom
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Medical Radioisotopes by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tc-99m
- 2.2.3 Cobalt-60
- 2.2.4 Iodine Radioisotopes
- 2.3 Medical Radioisotopes by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Nuclear Therapy
- 2.3.3 Equipment Radioactive Source
- 2.3.4 Diagnosis
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Medical Radioisotopes Breakdown Data by Type
- 3.1 Global Medical Radioisotopes Historic Market Size by Type (2021-2026)
- 3.2 Global Medical Radioisotopes Forecasted Market Size by Type (2027-2032)
4 Medical Radioisotopes Breakdown Data by Application
- 4.1 Global Medical Radioisotopes Historic Market Size by Application (2021-2026)
- 4.2 Global Medical Radioisotopes Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Medical Radioisotopes Market Perspective (2021-2032)
- 5.2 Global Medical Radioisotopes Growth Trends by Region
- 5.2.1 Global Medical Radioisotopes Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Medical Radioisotopes Historic Market Size by Region (2021-2026)
- 5.2.3 Medical Radioisotopes Forecasted Market Size by Region (2027-2032)
- 5.3 Medical Radioisotopes Market Dynamics
- 5.3.1 Medical Radioisotopes Industry Trends
- 5.3.2 Medical Radioisotopes Market Drivers
- 5.3.3 Medical Radioisotopes Market Challenges
- 5.3.4 Medical Radioisotopes Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Medical Radioisotopes Players by Revenue
- 6.1.1 Global Top Medical Radioisotopes Players by Revenue (2021-2026)
- 6.1.2 Global Medical Radioisotopes Revenue Market Share by Players (2021-2026)
- 6.2 Global Medical Radioisotopes Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Medical Radioisotopes Head Office and Area Served
- 6.4 Global Medical Radioisotopes Players, Product Type & Application
- 6.5 Global Medical Radioisotopes Manufacturers Established Date
- 6.6 Global Medical Radioisotopes Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Medical Radioisotopes Market Size (2021-2032)
- 7.2 North America Medical Radioisotopes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Medical Radioisotopes Market Size by Country (2021-2026)
- 7.4 North America Medical Radioisotopes Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Medical Radioisotopes Market Size (2021-2032)
- 8.2 Europe Medical Radioisotopes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Medical Radioisotopes Market Size by Country (2021-2026)
- 8.4 Europe Medical Radioisotopes Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Medical Radioisotopes Market Size (2021-2032)
- 9.2 Asia-Pacific Medical Radioisotopes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Medical Radioisotopes Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Medical Radioisotopes Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Medical Radioisotopes Market Size (2021-2032)
- 10.2 South America Medical Radioisotopes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Medical Radioisotopes Market Size by Country (2021-2026)
- 10.4 South America Medical Radioisotopes Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Medical Radioisotopes Market Size (2021-2032)
- 11.2 Middle East & Africa Medical Radioisotopes Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Medical Radioisotopes Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Medical Radioisotopes Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 NRG
- 12.1.1 NRG Company Information
- 12.1.2 NRG Business Overview
- 12.1.3 NRG Revenue in Medical Radioisotopes Business (2021-2026)
- 12.1.4 NRG Medical Radioisotopes Product Portfolio
- 12.1.5 NRG Recent Developments
- 12.2 IRE
- 12.2.1 IRE Company Information
- 12.2.2 IRE Business Overview
- 12.2.3 IRE Revenue in Medical Radioisotopes Business (2021-2026)
- 12.2.4 IRE Medical Radioisotopes Product Portfolio
- 12.2.5 IRE Recent Developments
- 12.3 ANSTO
- 12.3.1 ANSTO Company Information
- 12.3.2 ANSTO Business Overview
- 12.3.3 ANSTO Revenue in Medical Radioisotopes Business (2021-2026)
- 12.3.4 ANSTO Medical Radioisotopes Product Portfolio
- 12.3.5 ANSTO Recent Developments
- 12.4 NTP Radioisotopes
- 12.4.1 NTP Radioisotopes Company Information
- 12.4.2 NTP Radioisotopes Business Overview
- 12.4.3 NTP Radioisotopes Revenue in Medical Radioisotopes Business (2021-2026)
- 12.4.4 NTP Radioisotopes Medical Radioisotopes Product Portfolio
- 12.4.5 NTP Radioisotopes Recent Developments
- 12.5 China National Nuclear Corporation
- 12.5.1 China National Nuclear Corporation Company Information
- 12.5.2 China National Nuclear Corporation Business Overview
- 12.5.3 China National Nuclear Corporation Revenue in Medical Radioisotopes Business (2021-2026)
- 12.5.4 China National Nuclear Corporation Medical Radioisotopes Product Portfolio
- 12.5.5 China National Nuclear Corporation Recent Developments
- 12.6 Rosatom
- 12.6.1 Rosatom Company Information
- 12.6.2 Rosatom Business Overview
- 12.6.3 Rosatom Revenue in Medical Radioisotopes Business (2021-2026)
- 12.6.4 Rosatom Medical Radioisotopes Product Portfolio
- 12.6.5 Rosatom Recent Developments
- 12.7 Nordion
- 12.7.1 Nordion Company Information
- 12.7.2 Nordion Business Overview
- 12.7.3 Nordion Revenue in Medical Radioisotopes Business (2021-2026)
- 12.7.4 Nordion Medical Radioisotopes Product Portfolio
- 12.7.5 Nordion Recent Developments
- 12.8 Eckert & Ziegler Strahlen
- 12.8.1 Eckert & Ziegler Strahlen Company Information
- 12.8.2 Eckert & Ziegler Strahlen Business Overview
- 12.8.3 Eckert & Ziegler Strahlen Revenue in Medical Radioisotopes Business (2021-2026)
- 12.8.4 Eckert & Ziegler Strahlen Medical Radioisotopes Product Portfolio
- 12.8.5 Eckert & Ziegler Strahlen Recent Developments
- 12.9 Polatom
- 12.9.1 Polatom Company Information
- 12.9.2 Polatom Business Overview
- 12.9.3 Polatom Revenue in Medical Radioisotopes Business (2021-2026)
- 12.9.4 Polatom Medical Radioisotopes Product Portfolio
- 12.9.5 Polatom Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst